The Effect of Vildagliptin on Visfatin in Korean Patients with Type 2 Diabetes: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Prospective Study.
10.4093/jkd.2015.16.4.303
- Author:
Young Hwan JANG
1
;
Dong Hyun IN
;
Jae Kook YANG
;
Hyuk Jin MOON
;
Gyu Tae YOON
;
Ah Jeong RYU
;
Yeo Joo KIM
;
Eun Young LEE
;
Hyun Jin KIM
;
Bon Jeong KU
;
Jae Min LEE
;
Kang Seo PARK
;
In Suk LEE
;
Jong Min LEE
;
Dong Mee LIM
;
Keun Yong PARK
;
Sang Jin KIM
Author Information
1. Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea. ksj1113@schmc.ac.kr
- Publication Type:Multicenter Study ; Randomized Controlled Trial ; Original Article
- Keywords:
Diabetes mellitus;
Type 2;
Vildagliptin;
Visfatin
- MeSH:
Adipokines;
Adipose Tissue;
Biomarkers;
Blood Glucose;
Diabetes Mellitus;
Fasting;
Hemoglobin A, Glycosylated;
Humans;
Metformin;
Nicotinamide Phosphoribosyltransferase*;
Plasma;
Prospective Studies*
- From:Journal of Korean Diabetes
2015;16(4):303-309
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The effects of dipeptidyl peptidase-4 inhibitors on adipokines remain obscure. The aim of this study was to evaluate the effect of the addition of vildagliptin on visfatin, an adipokine that represents inflammatory biomarkers of adipose tissue, in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy. METHODS: In this 16-week, double-blind, randomized, parallel-group, placebo-controlled study, 71 patients were randomly assigned to vildagliptin 50 mg twice a day (n = 35) or placebo (n = 36) added to ongoing metformin therapy. Fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), plasma lipids, and visfatin levels were measured at baseline and 16 weeks after treatment. RESULTS: After 16 weeks, significant reduction in HbA1c and FPG was observed with vildagliptin addon treatment compared to placebo (-0.54 +/- 0.52%, P = 0.001 and -14.80 +/- 19.21 mg/dL, P = 0.004, respectively). However, no other clinically meaningful changes in lipid parameters or visfatin were observed. CONCLUSION: Vildagliptin add-on to metformin significantly improved fasting blood glucose and HbA1c. However, in this study, no significant differences in lipid parameters or visfatin level were observed between the two groups.
